Lung Cancer

Article	Citations
Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma	98
HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours	86
Real-world use of nivolumab plus ipilimumab in the management of diffuse pleural mesothelioma (DPM): experience from the county of Kent	72
Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study	61
Does consolidation radiotherapy to chest improve survival in extensive stage small cell lung cancer in the immunotherapy era? A retrospective study	60
Direct to CT screening pilot for patients with COPD in a deprived area: longitudinal analysis of the pulmonary nodule cohort outcomes	59
Prediction of next generation sequencing test failure in lung adenocarcinoma in a genomic laboratory hub setting	58
The role of mediastinoscopy following EBUS	53
Indwelling pleural catheter infections: a cautionary tale	52
Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma	52
Author index	51
Antimuscarinics and lung cancer survival: A Norwegian population-based cohort study	49
The first historical description of malignant mesotheliomas	46
Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study	45
190 Localised non-small cell lung cancer: patient characteristics and radical radiotherapy outcomes according to KRAS mutation status	44
175 External Validation of a Left Anterior Descending Coronary Artery Dose Constraint in Patients with Non-Small Cell Lung Cancer: An NI–HEART Analysis	44
Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer	44
98 Hospitalisation Rates following Systemic Anti-Cancer Treatments for Patients with Non-Small Cell Lung Cancer	43
107 Osimertinib Efficacy in Advanced NSCLC Patients with PACC and Classical-Like EGFR Mutations: A Retrospective Analysis from The Christie	43
101 Treating advanced EGFR positive non-small cell lung cancer patients with Osimertinib - the University Hospital Plymouth experience	43
86 Real World Outcomes of Patients Receiving Neoadjuvant Treatment for Non-Small Cell Lung Cancer	42
74 The first-in-class PRX3 inhibitor RSO-021 modulates the composition of malignant pleural effusions by eliciting immunomodulation and decreasing epithelial to mesenchymal protein expression	42
89 Why do almost half of our patients not complete 12 months of maintenance durvalumab after successful radical chemoradiotherapy?	41
Title Page	36
251 Optimising engagement and addressing inequalities for patients using a Digital Behaviour Change Intervention in lung cancer prehabilitation: A mixed-methods study	35

260 Second Primary Lung Cancer Cohort Study (SPORT)	35
190 Decision Making for Thoracic Radiotherapy and Prophylactic Cranial Irradiation in ES-SCLC Post Chemoimmunotherapy	33
108 Evaluation of a Lung Cancer Nurse led clinic for the routine follow up of uncomplicated post resection lung cancer patients	33
Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma: The importance of the lepidic proportion	33
Frailty, comorbidity and cardiovascular risk assessment in older patients with lung cancer	32
Contents	32
Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma	32
123 Using Prescribing Data to Estimate the Number of ALKpositive Patients Currently Living in England	32
Evaluating lung cancer risk factors in adults with interstitial lung disease	32
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer	31
WHO histological classification and tumor size are predictors of the locally aggressive behavior of thymic epithelial tumors	31
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial	31
Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group	31
Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation	31
Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study	31
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers	30
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer	30
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis	29
Functional resilience and overall survival in adults treated for advanced non-small-cell lung cancer	28
Clinical implementation of value based healthcare: Impact on outcomes for lung cancer patients	28
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial	28
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer	27
Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC	26
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry	26
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide	26
Clinical relevance of circulating activin A and follistatin in small cell lung cancer	25
Advances in the treatment of brain metastases in EGFR-mutant non-small cell lung cancer	25
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival	25
Cell pellet from fixative medium of transbronchial lung biopsy sample improves lung cancer ancillary test	25
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial	25
HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer	25
APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma	24
Spatial microenvironment heterogeneity in therapy-naïve lung cancer: A concept with more attention needed	24
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study	24
Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers	24
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score	24
Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board	23
219 “Fewer than 100 cigarettes in lifetime” deemed low risk for lung cancer – should we continue to offer Lung cancer screening to this cohort	23
Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas	23
195 The impact of measured versus estimated height and weight on lung cancer screening eligibility – analysis from the Yorkshire Lung Screening Trial	23
143 Comparative Evaluation of Clinical Frailty Scale and WHO Performance Status For Predicting 90-day and One-year Mortality in People with Lung Cancer	23
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the	23
206 Screening benefits and harms; a review of false positives and negatives from the Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Targeted Lung Health Check (TLHC) programme	23
Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis	23
37 Diagnostic performance across two high-volume EBUS services in Greater Manchester with and without Rapid On-Site Evaluation (ROSE)	22
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART	22
22 Challenges in Meeting Molecular Testing Turnaround Times in Lung Cancer	22
Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies	22
Clinicopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinoma	22
Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer	22

Assessing the impact of the pharmacist independent prescriber as part of the multi-disciplinary care of patients receiving adjuvant treatment for NSCLC	21
Contents	21
Contents	21
Contents	21
Contents	21
Analyzing diagnostic and treatment wait times for lung cancer Patients: Key insights from a provincial registry study	21
Initial experience of CT guided percutaneous microwave ablation of lung metastasis in a district general hospital	20
Lung cancer detection in the expanded Manchester Lung Health Check programme	20
Improving the use of NOACS for cancer-related VTE in Great Western Hospital	20
Two years on: progression free survival analysis of patients with advanced small cell lung cancer receiving atezolizumab plus etoposide and carboplatin in a tertiary oncology centre	20
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial	20
Real-world dosage, tolerability and clinical outcomes in patients with squamous NSCLC treated with carboplatin, paclitaxel and pembrolizumab in the West of Scotland	20
Impact and causes of readmission within 90-days of non-small cell lung cancer surgery	20
Rethinking continuity in primary care for people with mesothelioma	20
A District General Hospital (DGH) EBUS Service: a different model	20
Contents	20
The impact of real-world lung cancer screening programmes on downstream diagnostic capacity	20
67 The mental health and well-being implications of a mesothelioma diagnosis: a mixed methods study	19
Impact of introducing intensity modulated radiotherapy (IMRT) on curative intent radiotherapy and survival for lung cancer	19
Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene mutations identify a good prognostic factor	19
31 The Nodules of Norfolk, Setting up a Pulmonary Nodule Pathway in a secondary care setting at the Norfolk & Norwich University Hospital – A reflective study over one year from January 2023 – Jan	19
Crucial, complex, caring: a new professional development framework for Lung Cancer Nurse Specialists	19
204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design	19
135 The Impact of the Electronic Patient Record on Completion and Uploading of the Holistic Needs Assessment in Lung Cancer patients	19
69 New research-based resources to facilitate engagement with palliative care for patients and families living with mesothelioma	19
60 First-line Nivolumab/Ipilimumab in patients with unresectable malignant pleural Mesothelioma (MPM): West of Scotland experience	19
Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy	19
95 Lorlatinib in advanced ALK-rearranged NSCLC – real-world experience in a UK population	19
198 Pilot lung screening in Scotland: intervention findings and qualitative insights	18
Feasibility of salvage resection following locoregional failure after chemoradiotherapy and consolidation durvalumab for unresectable stage III non-small cell lung cancer	18
11 Making an accurate diagnosis of anterior mediastinal lesions: A proposal for a new diagnostic algorithm from the BTOG Thymic Interest Group	18
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)	18
Prognostic impact of extracapsular extension of lymph nodes in resected lung cancer: analysis by new N subcategories and histologic types	18
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure	18
Clinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancer	18
A combined model of circulating tumor DNA methylated SHOX2/SCT/HOXA7 and clinical features facilitates the discrimination of malignant from benign pulmonary nodules	18
109 Alk-positive NSCLC: Side effects - the real-world experiences of UK patients	18
Effect of adherence to treatment guidelines on overall survival in elderly non-small-cell lung cancer patients	18
Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment	18
Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities	18
Commentary on: Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning	17
Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis	17
70 Trial protocol and update for the DREM study	17
193 The Impact of a Targeted Lung Health Check Program on Oncology Services at UHCW	17
Mutational landscape of primary pulmonary salivary gland-type tumors through targeted next-generation sequencing	17
Unradical Surgery for Locally-Advanced Thymoma: Is it time to evolve Perspectives?	17
93 A regional-West Midlands audit on implementing the neo-adjuvant chemoimmunotherapy (NACIO) pathway for resectable non-small cell Cancer (NSCLC) patients	17
Spatiotemporal distribution of mediastinal neoplasms: A comprehensive multi-center study	17
56 High Frequency Jet Ventilation assisted CT guided lung biopsy service in a district general hospital	17
173 Real world outcomes for patients receiving radical radiotherapy for stage 3 Non-Small Cell Lung Cancer post-PACIFIC	17
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)	16
A case of lymphoepithelial carcinoma of the lung responding to treatment with pembrolizumab, paclitaxel and carboplatin	16
Optimisation of the treatment pathway for stage III non-small cell cancer (NSCLC) patients receiving concurrent chemo-radiation (cCRT)	16
Understanding the mental health and well-being impacts and interventions related to living with mesothelioma: a systematic review	16
BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations	16
Construction and validation of a clinical differentiation model between peripheral lung cancer and solitary pulmonary tuberculosis	16
Contents	16
Editorial Board	16
Contents	16
Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma	16
A machine learning approach using clinical data for recurrence risk-stratification following radiotherapy for non-small cell lung cancer	16
Evaluation of diagnostic algorithms for initial lung cancer investigation: are bundles safe and efficient?	16
Endobronchial ultrasound–transbronchial nodal aspiration (EBUS-TBNA) with rapid on-site evaluation (ROSE) in the Ulster Hospital, 2021	16
Research on the road: taking lung cancer research to the patient	15
Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study	15
169 Can reminders improve lung cancer screening uptake amongst higher-risk populations?	15
157 Establishing a multidisciplinary habilitation clinic for lung cancer patients receiving radical radiotherapy	15
Adherence to community-based lung cancer screening in the Yorkshire Lung Screening Trial	15
Corrigendum to “Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trial	15
A problem with clinical T factor in the 8th TNM edition: Prognosis and EGFR mutation status of small sized lung cancers with difficulty to measure the diameter of solid component in part-solid tumor	15
77 Toxicity and outcomes for patients with resected Non-Small cell lung cancer (NSCLC) who have received adjuvant chemotherapy in Bristol	15
Perceived barriers to curative treatment for patients with early stage lung cancer: a mixed methods study	15
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer	15
128 90 day admissions and mortality in lung cancer patients	15
46 Automated Derivation of Diagnostic Criteria for Lung Cancer using Natural Language Processing on Electronic Health Records: A pilot study	15
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis	14
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison	14
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking	14
Immunogenicity of COVID-19 vaccines in lung cancer patients	14
Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation	14

Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram	14
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions	14
Environmental asbestos exposure and lung cancer	14
Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib	14
54 A population-based review of early-onset lung cancer patients in Northern Ireland	14
Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations	14
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma	14
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment	14
Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib	13
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMS	13
Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden	13
Impact of perioperative fluids on clinical outcomes following thoracic surgery: a single-centre propensity matched retrospective study	13
Outcome of stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer (NSCLC)	13
The modification of T description according to visceral pleural invasion and tumor size from 3.1 cm to 4.0 cm in non-small cell lung cancer: A retrospective analysis based on the SEER database	13
Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition	13
PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC	13
Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 81	13
Implementing adjuvant immunotherapy following radical chemoradiotherapy for stage III non-small cell lung cancer in UK clinical practice: are the PACIFIC trial outcomes achievable in the real world?	13
174 The prevalence and clinical outcomes of incidental thymic lesions detected through Lung Cancer Screening	13
Asbestos-Related lung Cancer: An underappreciated oncological issue	13
Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma	13
118 Occupational causes of respiratory cancers: Current and emerging trends and promoting prevention	13
Editorial Board	13
Analyses of real-world data on patient outcomes in South Yorkshire, for patients with metastatic non-squamous lung cancer treated with pembrolizumab plus pemetrexed-platinum-based chemotherapy	13
Improving community lung cancer follow-up strategies in South Greater Glasgow and Clyde using 1-year survival data	12
The issue of no tissue: lung cancer patients without a tissue diagnosis in NHS Lothian	12
SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma	12
9 Evaluating outcomes in a district general hospital pleural service	12
18 The impact of radiology reporting delays on lung cancer care: A single centre experience	12
114 The role of the Patient Cancer Care Coordinator in the Lung Cancer Pathway – reducing health inequalities and optimising patient access	12
Hamlet.rt Trans: a prospective single-centre translational sub-study evaluation of liquid biomarkers of radiation response	12
EBUS audit: assessing the diagnostic performance of the service at UHL	12
Adjuvant immunotherapy after concurrent chemoradiation for locally advanced NSCLC: audit from Northern Ireland	12
Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report	12
109 Developing the role of the Lung Cancer Nurse Specialist (CNS) to support wider Clinical Practice beyond traditional role boundaries	12
A comparison of patient- and clinician-assessed performance status and the role of wearable activity trackers to assist in performance status assessment in advanced cancer patients	12
PRIMALung (EORTC-1901-LCG): prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small-cell lung cancer patients	12
Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-f	12
Contact with lung cancer patients during COVID-19: findings from Ireland and the UK from a global survey of patient experience	12
Contents	12
33 Implementation of a Lung Oncology Virtual Ward (VW) – Accelerating Responsiveness to Personalised Care Management	12
254 Quality of life after radiotherapy treatment for patients with stage IV non-small cell Lung cancer: QUARTZ LUNG a Candidate-Specific Trial within the TOURIST Platform	11
T cell immunity in interstitial lung disease with non-small cell lung cancer patients	11
Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study	11
Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy	11
Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study	11
257 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma	11
Corrigendum to “The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment” [Lung Cancer 165C (2022) 124–132]	11
132 A review of why patients with performance status 0-2 didn't receive anti-cancer treatment	11
Association between surgical quality and long-term survival in lung cancer	11
A quality improvement study aiming to quantify anti-emetic steroid usage and documentation of consent and adverse effects in lung cancer patients	11
Lung cancer caused by asbestos: What a reporting pathologist needs to know	11
Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer	11
Geographic variation in delay to surgical treatment among non-small cell lung cancer patients	11
Revisiting the lung cancer screening eligibility criteria to promote equity for Black individuals	11
51 Percutaneous tissue sampling in thoracic oncology - are core biopsies bigger and better?	11
86 Does entering clinical trials achieve better survival outcomes compared to standard of care in metastatic non-small cell lung cancer patients	11
57 Real-world insights from the ctDNA transformation pilot funded by NHS England for patients with advanced non-small cell lung cancer (NSCLC) in South East England	11
227 CT Characteristics in Small Cell Lung Cancer: Prognostic Markers and Paraneoplastic Syndrome Associations	11
Type of lymphadenectomy does not influence survival in pIa NSCLC patients who underwent VATS lobectomy: Results from the national VATS group database	11
Occupational asbestos exposure and survival among lung cancer patients	11
Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small	11
TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data	11
The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8+ T cell infiltration in Chinese lung large cell neuroendocrine carcinoma	11
182 Lung cancer findings from two Targeted Lung Health Check programmes running simultaneously across different geographically close regions and NHS trusts	11
ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report	10
Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients	10
75 Improving Research Access for Mesothelioma Patients (IRAMP)	10
Mesothelioma patient and carer experience: a study to identify research priorities	10
Implementation of a regional lung radiotherapy protocol in the UK	10
Process mining as a research tool to evaluate care pathways for patients with an indeterminate pulmonary nodule demonstrates the high variability between patient pathways across a region	10
Machine learning can predict lung cancer using primary care data	10
The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors	10
102 Real World Comparison between 1st line and 2nd line Osimertinib in Advanced/Metastatic EGFR mutated NSCLC at University Hospitals of Leicester.	10
187 Radiation pneumonitis following radical lung cancer radiotherapy: preliminary results from a logistic regression analysis	10
CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer	10
Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer	10
Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer	10
203 Setting up a county-wide targeted lung health check (TLHC) programme in Dorset, run through a district general hospital (DGH)	10
Moral distress in mesothelioma and lung cancer nurses during the COVID-19 pandemic: insights from a UK survey	10
Utility of PET-CT in the Lung Screen Uptake Trial	10
How can lung Multi-Disciplinary Team Meetings (MDTMs) be transformed? An audit of MDTM caseloads and processes between MDTs across a cancer alliance	10
Salford Targeted Lung Health Checks: a retrospective analysis of differences between responders and non-responders	10
133 Prevalence of Latent Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A South-East London Cohort Study	10
Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges	10
Real-world insights into patients with advanced NSCLC and MET alterations	10
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression	10
244 Recurrence pattern post surgical resection of lung cancer with curative intent	10
237 Assessing the effectiveness of talc pleurodesis in the prevention of malignant pleural effusions at the Royal Gwent Hospital, Newport	10
Is every PET positive lesion a lung cancer? Eight years outcome from a tertiary care hospital	10
Outcomes of open access to CT scanning in suspected lung malignancy in patients in Lincolnshire	10
Editorial Board	10
45 Optimisation of an EBUS service at a district general hospital	10
82 UK real world study of patients who do not proceed to surgery following neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer (NSCLC)	10
Asbestos Surveillance Program Aachen (ASPA): Cancer mortality among asbestos exposed power industry workers	9